Yarmouk University has signed an agreement with the Ministry of Higher Education and Scientific Research to fund an innovative research project led by Dr. Ali Hmedat, a faculty member in the Department of Pharmaceutics and Pharmaceutical Technology at the Faculty of Pharmacy. The project was selected for support by the Scientific Research and Innovation Support Fund at the Higher Council for Science and Technology.

The funded project is titled:

Assessment of SRC, MET, IGF2BP1, EGFR, and p130CAS Levels in Jordanian Patients with Head and Neck Cancer: Correlations with Risk Factors, Clinical Parameters, and Predictive Outcomes.

The project team also includes Dr. Mohammad Alarjani from Jordan University of Science and Technology.

This research aims to evaluate the expression and activity levels of the proteins EGFR, MET, IGF2BP1, p130CAS, and SRC in tumor samples from head and neck cancer patients treated at King Abdullah University Hospital. The study will analyze the relationship between these biomarkers and patients’ clinical and pathological characteristics, risk factors, and survival outcomes.

By identifying molecular markers associated with poor prognosis, the project aspires to guide the development of more precise and effective targeted therapies tailored to Jordanian patients. This reflects Yarmouk University’s commitment to advancing impactful cancer research and enhancing the national capacity for precision oncology.